It takes decades of research, millions of dollars in funding, and numerous failed attempts to develop and approve a new drug for patients. Private investors have helped fund pharmaceutical research and development to bring patients life-saving medicine – but recent policy changes may slow that process down.
Venture capitalist Stan Fleming explains why the industry needs this investment to fund projects that can deliver new therapies to patients with rare and chronic diseases. And, why new policies could deter investors from funding high-risk research projects, particularly for Alzheimer’s and cancer.
Plus, hear from scleroderma advocate Amy Gietzen, as she recaps her time at the We the Patients Fly-In.
Dr. Robert Goldberg, “Dr. Bob,” Co-Founder and Vice President of the Center for Medicine in the Public Interest
Kate Pecora, Field Correspondent
Amy Gietzen, advocate and patient living with systemic scleroderma
Leslie Davis-Primo, Patient Correspondent
The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands? Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.org
Have a question or comment about the show, or want to suggest a show topic or share your story as a patient correspondent?
Drop us a line: email@example.com
The views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising, nor do the views and opinions stated on this show reflect the opinions of a guest’s current or previous employers.